Professional
Added to YB: 2025-05-30
Pitch date: 2025-05-28
TEM [bearish]
Tempus AI, Inc.
-28.97%
current return
Author Info
Spruce Point Capital Management is an activist investment manager specializing in forensic short-selling. Sign up for the newsletter.
Company Info
Tempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties.
Market Cap
$12.5B
Pitch Price
$54.75
Price Target
21.30 (-70%)
Dividend
N/A
EV/EBITDA
-82.74
P/E
-59.11
EV/Sales
11.84
Sector
Life Sciences Tools and Services
Category
N/A
Spruce Point Capital Management Issues 'Strong Sell' Research Opinion On Tempus AI, Inc. (Nasdaq: TEM)
TEM: Founder Lefkofsky's history of overhyped IPOs raises red flags. Only 2% of revenue from AI despite rebranding. Multiple board members linked to accounting restatements. Suspicious Softbank JV, aggressive TCV reporting, related-party Pathos deal, and weakening AstraZeneca partnership. 77% of rev paid as stock comp with insiders selling. 50-60% downside vs 1% upside at $66.82 PT.
Read full article (8 min)